These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 6499689

  • 1. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy].
    Becker G, Goossens H, Seemann K, Souchon F, Weitz T.
    Dtsch Med Wochenschr; 1984 Dec 07; 109(49):1881-5. PubMed ID: 6499689
    [Abstract] [Full Text] [Related]

  • 2. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z, Shupak A, Gordon CR.
    Clin Pharmacokinet; 2006 Dec 07; 45(6):543-66. PubMed ID: 16719539
    [Abstract] [Full Text] [Related]

  • 3. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct 07; 25(5):299-302, 319. PubMed ID: 2076342
    [Abstract] [Full Text] [Related]

  • 4. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L.
    Clin Pharmacol Ther; 1984 Jul 07; 36(1):116-20. PubMed ID: 6734040
    [Abstract] [Full Text] [Related]

  • 5. [Transdermally applied scopolamine for continuous prevention of motion sickness. Revival of a 150-year-old method].
    Becker G.
    Schweiz Rundsch Med Prax; 1985 Mar 12; 74(11):271-6. PubMed ID: 3887535
    [No Abstract] [Full Text] [Related]

  • 6. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME, Royal JW, Shaw JE, Schmitt LG.
    Aviat Space Environ Med; 1979 Nov 12; 50(11):1108-11. PubMed ID: 393242
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF, Bongaerts MC, Christiaanse JC, Hofkamp HG, van Ouwerkerk W.
    Clin Pharmacol Ther; 1985 Sep 12; 38(3):301-5. PubMed ID: 4028625
    [Abstract] [Full Text] [Related]

  • 9. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions].
    Offenloch K, Zahner G, Dietlein G, Franz I.
    Arzneimittelforschung; 1986 Sep 12; 36(9):1401-6. PubMed ID: 3539128
    [Abstract] [Full Text] [Related]

  • 10. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Clissold SP, Heel RC.
    Drugs; 1985 Mar 12; 29(3):189-207. PubMed ID: 3886352
    [Abstract] [Full Text] [Related]

  • 11. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S, Shapira S, Zilbiger A, Ribak J.
    Aviat Space Environ Med; 1984 Nov 12; 55(11):1051-4. PubMed ID: 6508687
    [Abstract] [Full Text] [Related]

  • 12. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G.
    Clin Pharmacol Ther; 1981 Mar 12; 29(3):414-9. PubMed ID: 7009021
    [Abstract] [Full Text] [Related]

  • 13. [Transdermal scopolamine (TTS-scopolamine) for the prevention of postoperative nausea and vomiting].
    Tolksdorf W, Meisel R, Müller P, Bender HJ.
    Anaesthesist; 1985 Dec 12; 34(12):656-62. PubMed ID: 4096357
    [Abstract] [Full Text] [Related]

  • 14. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL, Kohl RL, Reschke MF, Degioanni J, Cintron-Trevino NM.
    Aviat Space Environ Med; 1983 Nov 12; 54(11):994-1000. PubMed ID: 6651736
    [Abstract] [Full Text] [Related]

  • 15. The Republic of Singapore Navy's Scopoderm TTS study: results after 2,200 man-days at sea.
    How J, Lee PS, Seet LC, Tan PK.
    Aviat Space Environ Med; 1988 Jul 12; 59(7):646-50. PubMed ID: 3044323
    [Abstract] [Full Text] [Related]

  • 16. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O, Laitinen LA, Aho J, Gothoni G, Vapaatalo H.
    Aviat Space Environ Med; 1984 Jul 12; 55(7):636-41. PubMed ID: 6466260
    [Abstract] [Full Text] [Related]

  • 17. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness.
    Pyykkö I, Schalén L, Jäntti V.
    Acta Otolaryngol; 1985 Jul 12; 99(5-6):588-96. PubMed ID: 4024909
    [Abstract] [Full Text] [Related]

  • 18. [Study on effect of acupoint sticker of TTS-ST93-1 in treating motion sickness].
    Pei J, Yang T, Liu Z.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 Aug 12; 18(8):464-7. PubMed ID: 11477828
    [Abstract] [Full Text] [Related]

  • 19. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN, Ezzo DC.
    Am J Health Syst Pharm; 2009 Nov 15; 66(22):2024-6. PubMed ID: 19890085
    [Abstract] [Full Text] [Related]

  • 20. Transdermal scopolamine in motion sickness.
    Cronin CM, Sallan SE, Wolfe L.
    Pharmacotherapy; 1982 Nov 15; 2(1):29-31. PubMed ID: 6927209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.